Amino Acids

, Volume 14, Issue 1, pp 75–82

Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease

  • L. Verhagen Metman
  • P. Del Dotto
  • P. J. Blanchet
  • P. van den Munckhof
  • T. N. Chase
Full Paper

DOI: 10.1007/BF01345246

Cite this article as:
Metman, L.V., Del Dotto, P., Blanchet, P.J. et al. Amino Acids (1998) 14: 75. doi:10.1007/BF01345246

Summary

In animal models of Parkinson's disease (PD), glutamate antagonists diminish levodopa (LD)-associated motor fluctuations and dyskinesias. We sought to investigate if these preclinical observations can be extended to the human disease, by evaluating the effects of three non-competitive NMDA antagonists (dextrorphan, dextromethorphan and amantadine) on the motor response to LD in patients with advanced PD. In four separate trials, adjuvant therapy with these drugs reduced LD-induced dyskinesias and motor fluctuations. These findings support the view that drugs acting to inhibit glutamatergic transmission at the NMDA receptor can ameliorate LD associated motor response complications.

Keywords

NMDA antagonistsMotor response complications

Copyright information

© Springer-Verlag 1998

Authors and Affiliations

  • L. Verhagen Metman
    • 1
  • P. Del Dotto
    • 1
  • P. J. Blanchet
    • 1
  • P. van den Munckhof
    • 1
  • T. N. Chase
    • 1
  1. 1.Experimental Therapeutics Branch, National Institute of Neurological Diseases and StrokeNational Institutes of HealthBethesdaUSA